Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer: a model-based economic evaluation
Purpose - The aim of this study was to analyze the cost-effectiveness of screening patients of intermediate risk of breast cancer with MR-Mammography (MRM) versus conventional mammography (XM). - Method - A decision model for both diagnostic modalities and a subsequent markov model for the simulatio...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 2021
|
| In: |
European journal of radiology
Year: 2021, Volume: 136, Pages: 1-7 |
| ISSN: | 1872-7727 |
| DOI: | 10.1016/j.ejrad.2020.109355 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejrad.2020.109355 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0720048X20305441 
|
| Author Notes: | Clemens G. Kaiser, Matthias Dietzel, Tibor Vag, Matthias F. Froelich |
| Summary: | Purpose - The aim of this study was to analyze the cost-effectiveness of screening patients of intermediate risk of breast cancer with MR-Mammography (MRM) versus conventional mammography (XM). - Method - A decision model for both diagnostic modalities and a subsequent markov model for the simulation of follow-up costs and outcomes was developed. Input parameters were acquired from published literature for this markov modelling study. The expected cumulative costs and outcomes were calculated for both modalities in a 30-year timeframe in US-dollar ($) and quality-adjusted life years (QALYs). A deterministic sensitivity analysis and a probabilistic sensitivity analysis incorporating 30,000 Monte Carlo iterations were performed to investigate the model stability. - Results - In total, XM with its consecutive treatments resulted in total costs of $ 5,492.68 and an average cumulative quality of life of 18.87 QALYs, compared to MRM with costs of $ 5,878.66 and 18.92 QALYs. The corresponding incremental cost-effectiveness ratio (ICER) for MRM was $ 8,797.60 per QALY - distinctly below international willingness-to-pay thresholds for cost-effectiveness. The results were confirmed within the limits of the sensitivity analyses. - Conclusions - In patients with intermediate risk for breast cancer due to their dense breast tissue, two-yearly screening with MRM may be considered as cost-effective. |
|---|---|
| Item Description: | Gesehen am 16.08.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1872-7727 |
| DOI: | 10.1016/j.ejrad.2020.109355 |